当前位置:
X-MOL 学术
›
J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
1-Aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives. A new series of potential antidepressants.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 1987 Feb Bonnaud, B, Cousse, H, Mouzin, G, Briley, M, Stenger, A, Fauran, F, Couzinier, J P
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 1987 Feb Bonnaud, B, Cousse, H, Mouzin, G, Briley, M, Stenger, A, Fauran, F, Couzinier, J P
A series of 1-aryl-2-(aminomethyl)cyclopropanecarboxylic acid derivatives were synthesized and evaluated as potential antidepressants. Compounds with the Z configuration were synthesized from 1-aryl-2-oxo-3-oxabicyclo[3.1.0]hexane and those with the E configuration from (E)-1-phenyl-2-(hydroxymethyl)cyclopropanecarboxylic acid. The compounds were evaluated in animal tests designed to reveal potential antidepressant activity and the existence of undesirable side effects. Several derivatives were more active than imipramine and desipramine. On the basis of its activity in pharmacological animal tests of antidepressant activity and its potential lack of side effects, 1-phenyl-1-[(diethylamino)carbonyl]-2- (aminomethyl)cyclopropane hydrochloride, midalcipran (INN), was selected for further development. This compound is currently in phase III clinical evaluation.
中文翻译:
1-芳基-2-(氨基甲基)环丙烷羧酸衍生物。一系列潜在的抗抑郁药。
合成了一系列的1-芳基-2-(氨基甲基)环丙烷羧酸衍生物,并作为潜在的抗抑郁药进行了评估。具有Z构型的化合物由1-芳基-2-氧代-3-氧杂双环[3.1.0]己烷合成,具有E构型的化合物由(E)-1-苯基-2-(羟甲基)环丙烷羧酸合成。在动物试验中对化合物进行了评估,旨在揭示其潜在的抗抑郁活性和不良副作用的存在。几种衍生物比丙咪嗪和地昔帕明更具活性。根据其在抗抑郁药理动物实验中的活性及其潜在的无副作用,选择了1-苯基-1-[((二乙基氨基)羰基] -2-(氨基甲基)环丙烷盐酸盐,中alcipranan(INN)。进一步的发展。
更新日期:2017-01-31
中文翻译:
1-芳基-2-(氨基甲基)环丙烷羧酸衍生物。一系列潜在的抗抑郁药。
合成了一系列的1-芳基-2-(氨基甲基)环丙烷羧酸衍生物,并作为潜在的抗抑郁药进行了评估。具有Z构型的化合物由1-芳基-2-氧代-3-氧杂双环[3.1.0]己烷合成,具有E构型的化合物由(E)-1-苯基-2-(羟甲基)环丙烷羧酸合成。在动物试验中对化合物进行了评估,旨在揭示其潜在的抗抑郁活性和不良副作用的存在。几种衍生物比丙咪嗪和地昔帕明更具活性。根据其在抗抑郁药理动物实验中的活性及其潜在的无副作用,选择了1-苯基-1-[((二乙基氨基)羰基] -2-(氨基甲基)环丙烷盐酸盐,中alcipranan(INN)。进一步的发展。